Search company, investor...

Predict your next investment

Venture Capital
borealis.vc

Investments

99

Portfolio Exits

21

Funds

5

Partners & Customers

1

About Borealis Ventures

Borealis Ventures partners closely with exceptional entrepreneurs to build market-defining companies. Its focus is on the opportunities to transform healthcare through new therapies, digital innovation, and other technologies.

Headquarters Location

10 Allen St., Upper Level

Hanover, New Hampshire, 03755,

United States

603.643.1500

Want to inform investors similar to Borealis Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Borealis Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Borealis Ventures in 1 Expert Collection, including Travel Technology (Travel Tech).

T

Travel Technology (Travel Tech)

39 items

Tech-enabled companies offering services and products focused on tourism. This collection includes booking services, search platforms, on-demand travel and recommendation sites, among others.

Latest Borealis Ventures News

T-Cypher Bio separates from Orbit Discovery to build a

Nov 1, 2022

pipeline of TCR therapeutics for solid tumours and other indications Company has potential to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases. Closed financing led by Oxford Sciences Innovation with participation from RT Ventures, Borealis Ventures, University of Oxford, and a private investor Oxford, UK, 25 February 2021 – T-Cypher Bio (‘T-Cypher’, or ‘the Company’), a rapidly emerging private biotech company pioneering a novel approach to TCR therapeutics has launched today. Established in late 2020, T-Cypher has separated from Orbit Discovery (“Orbit”) to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation of T-Cypher has been financed by Oxford Sciences Innovation (“OSI”) with participation from RT Ventures, Borealis Ventures, the University of Oxford, and a private investor. All investors were original Orbit investors. Over the past nine months, OSI has worked closely with co-founder, Graham Ogg and the Orbit team to aid in the formation of T-Cypher adding an experienced management team and leading advisers. T-Cypher will use its proprietary bead-display microfluidic platform to investigate a broad target landscape identified through bespoke immunopeptidomics. The company will focus on identifying targets within new antigen classes that have not been explored with existing technologies. Its functional high-throughput approach allows the company to interrogate TCR-specificity without the need for laborious T cell cloning or soluble-TCR generation and will allow for the identification of a broad-range of therapeutically relevant antigen:TCR pairs. Commenting on the development, Professor Graham Ogg, Co-founder and SAB Chair of T-Cypher and Professor of Dermatology at the University of Oxford, and Past Director of the MRC Human Immunology Unit, WIMM, said: "T-Cypher has the leading technology in the field for deconvoluting vast T cell repertoires, enabling development of the adaptive immune therapeutics of the future. Its innovative bead-based microfluidic platform enables high-throughput functionality testing of T cells directly from patients. I’m excited to be supporting the team in building an end-to-end business to establish a pipeline of TCR based products.” Commenting on the formation of T-Cypher, Uciane Scarlett, PhD, Interim Executive Chair & OSI Investment Principal, said: “Working hand-in-hand with Graham we have built a specialised team that is aligned with the Company’s ambitious goals. Research within Orbit over the past few years allows T-Cypher to hit the ground running and immediately begin work to generate new TCR therapies in both oncology and non-oncology. We are delighted to work closely with T-Cypher in its formation and beyond. We’re very confident in the company’s future growth.” Commenting on the challenges and benefits of T-Cypher, Dr Luke Williams, Interim Head of Research and Development, and OSI Scientist-in-Residence said: “T-Cypher’s approach overcomes many of the challenges that other companies have faced when selecting therapeutically relevant targets for immunotherapies. Our ability to identify a broad range of potential targets and use our platform to interrogate immune responses in patients of interest, will be a significant step forward in this rapidly growing sector. I’m excited to be working with such a strong team to develop the next generation of TCR-based treatments.” The company will remain in stealth as it focuses on building out its platform and pipeline. - Ends - About T-Cypher Bio T-Cypher Bio, a rapidly emerging biotechnology company headquartered in Oxford, UK, is pioneering a novel approach to develop next generation TCR therapeutics and utilise state of the art techniques to identify a broad-range of potential targets, for both solid tumours and other indications. These techniques offer a vast library of candidate antigen peptides for recognition by T cells and the ability to test T cell functionality directly from patients without the need for T cell cloning, TCR generation or immortalised T cells. Through harnessing the knowledge gained within Orbit Discovery, the Company is building a pipeline of game-changing treatments for patients, with the potential to save lives. For more information please visit: https://tcypherbio.com/ About OSI Oxford Sciences Innovation is a leading science and technology business. OSI ensures Oxford’s world-leading science moves out of the laboratory and onto the global stage. In partnership with the University of Oxford, OSI creates fundamental technology companies, built on science. We match scientists with experienced entrepreneurs and patient capital to turn idea to impact, discovery to company. OSI invests in Life Sciences, Deep Tech, Healthtech, AI and Software to create companies taking on challenges like diagnosis and treatment of disease and cancer, hyper resolution microscopy, renewable energy, drones, nuclear fusion and quantum computing. Founded in 2015, we’ve raised over $800M of evergreen capital, building on Oxford’s renowned research legacy, to create a leading science and technology ecosystem and home for entrepreneurs. OSI backs companies from their inception and invest for the long-term, helping them to build their businesses by finding senior management talent, entrepreneurs, expert advisors and global investors to realise their vision. OSI reinvests any returns back into the Oxford ecosystem and the next generation of scientists and technologies to create even more companies capable of tackling more of the world’s most important problems. About RT Ventures Founded in 2016 RT Ventures is a leading investor in UK University spin-out companies, with a focus on life science and healthcare technology. About Borealis Venture Borealis Ventures is an early-stage venture capital firm partnering closely with exceptional entrepreneurs since 2002 to build visionary healthcare companies. Borealis focuses on life science platforms, digital health, and animal health opportunities, often involving the translation of university-based innovation. For more information, please visit: www. borealis.vc . About The University of Oxford The University of Oxford has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. Through its research commercialisation arm, Oxford University Innovation, Oxford is the leading university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.

Borealis Ventures Investments

99 Investments

Borealis Ventures has made 99 investments. Their latest investment was in Anada as part of their Unattributed VC on June 6, 2023.

CBI Logo

Borealis Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/23/2023

Unattributed VC

Anada

$2.22M

Yes

1

6/1/2022

Seed VC

Amagma Therapeutics

$2.28M

Yes

1

1/20/2022

Series B

Blue Rabbit

$13.64M

Yes

1

9/8/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/20/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2023

6/1/2022

1/20/2022

9/8/2021

7/20/2021

Round

Unattributed VC

Seed VC

Series B

Series B

Series B

Company

Anada

Amagma Therapeutics

Blue Rabbit

Subscribe to see more

Subscribe to see more

Amount

$2.22M

$2.28M

$13.64M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Borealis Ventures Portfolio Exits

21 Portfolio Exits

Borealis Ventures has 21 portfolio exits. Their latest portfolio exit was Blue Rabbit on June 14, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/14/2023

Merger

$99M

1

9/16/2021

Acquired

$99M

4

7/21/2021

Acquired

$99M

8

6/23/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

2/14/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2023

9/16/2021

7/21/2021

6/23/2020

2/14/2019

Exit

Merger

Acquired

Acquired

Reverse Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

4

8

10

10

Borealis Ventures Acquisitions

2 Acquisitions

Borealis Ventures acquired 2 companies. Their latest acquisition was Vico Software on March 23, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/23/2007

Series B

$99M

$3.6M

Acquired

6/30/2004

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/23/2007

6/30/2004

Investment Stage

Series B

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$3.6M

Note

Acquired

Subscribe to see more

Sources

10

Borealis Ventures Fund History

5 Fund Histories

Borealis Ventures has 5 funds, including Vox Health Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/27/2020

Vox Health Fund

$12.05M

1

9/6/2018

Built Environment Innovation Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

12/5/2012

Borealis Granite Fund

Subscribe to see more

Subscribe to see more

$99M

10

5/30/2003

The Borealis Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Borealis Ventures II

Subscribe to see more

Subscribe to see more

10

Closing Date

1/27/2020

9/6/2018

12/5/2012

5/30/2003

Fund

Vox Health Fund

Built Environment Innovation Fund LP

Borealis Granite Fund

The Borealis Fund LP

Borealis Ventures II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$12.05M

$99M

$99M

$99M

Sources

1

10

10

10

10

Borealis Ventures Partners & Customers

1 Partners and customers

Borealis Ventures has 1 strategic partners and customers. Borealis Ventures recently partnered with Johnson & Johnson, and Dartmouth College on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/27/2017

Partner

United States

News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners).

`` It will be an active partnership with Johnson & Johnson and Borealis Ventures .

1

Date

11/27/2017

Type

Partner

Business Partner

Country

United States

News Snippet

News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners).

`` It will be an active partnership with Johnson & Johnson and Borealis Ventures .

Sources

1

Borealis Ventures Team

3 Team Members

Borealis Ventures has 3 team members, including , .

Name

Work History

Title

Status

Jesse F. Devitte

Green Launching Pad, Autodesk, Softdesk, and White House

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Jesse F. Devitte

Subscribe to see more

Subscribe to see more

Work History

Green Launching Pad, Autodesk, Softdesk, and White House

Title

Founder

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.